RT Conference Proceedings
T1 Fasentin, a glucose uptake inhibitor, is also able to inhibit angiogenesis
A1 Ocaña Farfán, María del Carmen
A1 Carrillo Fernández, Paloma
A1 Martínez-Póveda, Beatriz Amparo
A1 Rodríguez-Quesada, Ana María
A1 Medina-Torres, Miguel Ángel
K1 Antiangiogénicos
AB The role of glucose on endothelial cell (EC) metabolism and angiogenesis has been an emerging issue in the last few years. Some inhibitors of glucose metabolism, such as 2-deoxyglucose, have been shown to have anti-angiogenic effects. Fasentin is a poor-studied inhibitor of glucose uptake which modulates GLUT-1 and GLUT-4 transporters in cancer cells. We wanted to test its possible effect on EC glucose uptake, showing a light decrease in HMEC at 100 µM. Lower doses did not affect this characteristic of glucose metabolism. In line with this fact, fasentin at 100 µM totally inhibited tube formation on Matrigel in these cells. This anti-angiogenic effect is not likely to be helped by a pro-apoptotic effect of fasentin but, as proved with additional assays, it could be due to a decrease on the signaling for extracellular matrix degradation. More research would be necessary in order to elucidate its fine regulation on angiogenesis and metabolism.
YR 2017
FD 2017-10-31
LK http://hdl.handle.net/10630/14739
UL http://hdl.handle.net/10630/14739
LA eng
NO Es comunicación a congreso en formato póster
NO Universidad de Málaga. Campus de Excelencia Internacional Andalucía Tech.                       [Our experimental work is supported by grants BIO2014-56092-R (MINECO and FEDER) and P12-CTS-1507 (Andalusian Government and FEDER) and funds from group BIO-267 (Andalusian Government). The "CIBER de Enfermedades Raras" is an initiative from the ISCIII (Spain). This communicaction has the support of a travel grant "Universidad de Málaga. Campus de Excelencia Internacional Andalucía Tech"].
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 10 abr 2026